MSH2 and neoplasm: Conversely, ubiquitous mutations in PR0103 were mainly associated with Signature 1 (age), suggesting that MMRD was not an initial driver of this tumour, but rather the acquired biallelic loss of MSH2 was a later event that provided a selective advantage, possibly through an accelerated mutation rate.